Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Amgen AMGN and Bristol Myers Squibb BMY are among the largest global biotechnology companies with broad and diverse ...

Amgen is also scheduled to report new data from the CodeBreak-101 study of the drug, in combination with its EGFR inhibitor Vectibix (panitumumab), in KRAS-mutated colorectal cancer at the ESMO ...

Amgen’s oncology portfolio achieved a number of successes too, with Kepivance being approved for oral mucositis as a side effect of chemotherapy in 2004, and monoclonal antibody Vectibix ...

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell ...

Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ...